Ceapro Stock

Ceapro Liabilities

Delisted

The The Liabilities of Ceapro (CZO.V) as of Aug 22, 2026 is 3.59 M CAD. In the previous year, The Liabilities was 5.45 M CAD — a change of -34.06% (lower).

Liabilities

3.59 MCAD

YoY

-34.06%

Last updated:

In 2026, Ceapro's total liabilities amounted to 3.59 M CAD, a -34.06% difference from the 5.45 M CAD total liabilities in the previous year.

The Ceapro Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2016
3.99 M CAD
Jan 1, 2017
5.26 M CAD
Jan 1, 2018
2.11 M CAD
Jan 1, 2019
4.96 M CAD
Jan 1, 2020
4.91 M CAD
Jan 1, 2021
3.33 M CAD
Jan 1, 2022
5.45 M CAD
Jan 1, 2023
3.59 M CAD
The Ceapro Liabilities history
YEARLiabilitiesYoY
3.59 MCAD-34.06%
5.45 MCAD+63.48%
3.33 MCAD-32.21%
4.91 MCAD-0.87%
4.96 MCAD+134.97%
2.11 MCAD-59.92%
5.26 MCAD+31.90%
3.99 MCAD-49.01%
7.83 MCAD+39.99%
5.59 MCAD
Access this data via the Eulerpool API

Ceapro Stock analysis

What does Ceapro do? Ceapro Inc is an innovative biotechnology company based in Edmonton, Canada. The company was founded in 1997 and has since specialized in the development of natural, biological ingredients from plants. It is listed on the Toronto Stock Exchange and has become a key player in the field of natural-based medicine and cosmetics in recent years. Ceapro's business model is based on the research and production of active compounds from plant-based raw materials. The company employs gentle extraction methods that preserve the effectiveness of the ingredients and enable environmentally friendly production. Ceapro collaborates closely with research and industry to ensure the best possible effectiveness and applicability of its products. The company's products are divided into various segments tailored to the needs of customers. One important segment is medicine, where Ceapro focuses on the development of herbal remedies. The company has already developed some promising products in this area, which can be used, for example, for inflammation, pain, or diabetes. Another important segment of Ceapro is cosmetics, where the company researches and produces natural ingredients for skin and hair care. These products are known for their high effectiveness, tolerability, and environmental friendliness. One of the company's most famous products is Avenanthramide, an ingredient derived from oats that offers anti-aging and anti-inflammatory properties. Ceapro also places special emphasis on the development of digestive-aid ingredients that can be used in the food industry. The company relies on plant enzymes and compounds that help support and relieve the digestive system. The use of natural ingredients ensures high tolerability and usability. Over the course of its history, Ceapro Inc has already won numerous awards and prizes that confirm the high quality of its products and the company's innovative power. For example, the company has been repeatedly honored with the Alberta Venture Fast Growth 50 Award and also received the Environmental Stewardship Award from the Edmonton Chamber of Commerce. Ceapro is not only an innovative biotechnology company specializing in the research and production of plant-based ingredients but also an important player in the fields of medicine and cosmetics. The company employs gentle extraction methods and collaborates closely with research and industry to achieve the best possible effectiveness and applicability. The different products are divided into the segments of medicine, cosmetics, and food and are known for their high effectiveness, tolerability, and environmental friendliness. Ceapro is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Ceapro's Liabilities

Ceapro's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ceapro's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ceapro's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ceapro's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ceapro’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ceapro stock

The Liabilities of Ceapro is 3.59 M CAD in 2026.

The Liabilities of Ceapro changed from 5.45 M CAD to 3.59 M CAD, representing a -34.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Ceapro since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Ceapro historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Ceapro

All Key Metrics — Ceapro